Title:Pharmacophore Mapping of Ligand Based Virtual Screening, Molecular Docking and Molecular Dynamic Simulation Studies for Finding Potent NS2B/NS3 Protease Inhibitors as Potential Anti-dengue Drug Compounds
VOLUME: 13 ISSUE: 6
Author(s):A. Jainul Fathima*, G. Murugaboopathi and P. Selvam
Affiliation:Department of CSE, School of Computing, Kalasalingam University, Krishnankoil, Tamilnadu, Department of CSE, School of Computing, Kalasalingam University, Krishnankoil, Tamilnadu, Research Faculty, Sir C.V. Raman, K.S. Krishnan International Research Centre, Kalasalingam University, Krishnankoil, Tamilnadu
Keywords:Dengue NS2B/NS3 protease, virtual highthroughputscreening, bromocriptine, ZINC92615064, pharmacophoremodelling,
de novo simulation.
Abstract:Background: Dengue virus (DENV) has become a crucial health concern. The NS2B/NS3
Protease is a major drug target for DENV in rational drug design. At present, effective treatment of
DENV is not possible due to unavailability of specific anti-viral drugs. Based on the drug repurposing
studies, bromocriptine compound was found to be a potent anti-DENV drug-like compound and it is
also an approved drug for treatment of other diseases.
Materials and Methods: Taking bromocriptine as a lead compound, in the current research,
pharmacophore feature based virtual screening was performed to find an effective target specific
protease inhibitors.
Results: Out of 40,000 bromocriptine similar compounds screened against NS2B/NS3 protease drug
target, the ZINC92615064 compound was found to be highly potent compared to bromocriptine based
on its compared binding energies and ADMET properties. To further validate the results, molecular
dynamic simulations for NS2B/NS3 protease in complex with bromocriptine compared to NS2B/NS3
protease in complex with ZINC92615064 were performed for 20 nanoseconds for understanding its
plausible mode of action.
Conclusion: The outcome of the present study exposed several potent dengue NS2B/NS3 protease
inhibitors which are worth considering for further clinical studies.
